Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

NCT00264160 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Chronic

Interventions

DRUG: AMN107

Sponsor

Novartis Pharmaceuticals